A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD)

Maya Koren-Michowitz, Avichai Shimoni, Asaf Vivante, Luba Trakhtenbrot, Gideon Rechavi, Ninette Amariglio, Ron Loewenthal, Arnon Nagler, Yoram Cohen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

JAK2 V617F mutation is found in a high proportion of MPD patients. We developed a quantitative assay for the detection of the JAK2 mutation and demonstrated its clinical utility in MPD patients who underwent SCT. Sixty percent of the patients were JAK2 V617F positive prior to the SCT (mean mutation levels 74%, range 16-98%). After the procedure, the mutation levels progressively decreased and were in correlation with the donor-recipient chimerism status (r = 0.97, p < 0.001). At a median follow up of 16 months (range 2-58), 9/15 patients are alive and in CR. The levels of the JAK2 V617F mutation reached 0% in all surviving patients.

Original languageEnglish
Pages (from-to)421-427
Number of pages7
JournalLeukemia Research
Volume32
Issue number3
DOIs
StatePublished - Mar 2008

Keywords

  • Allo SCT
  • JAK2 V617F
  • MALDI-TOF
  • Myeloproliferative disorders

Fingerprint

Dive into the research topics of 'A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD)'. Together they form a unique fingerprint.

Cite this